查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836884

血浆蛋白治疗市场（按产品、适应症、给药途径和最终用户划分）—全球预测 2025-2032

Plasma Protein Therapeutics Market by Product, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年血浆蛋白治疗市场将成长至 878.1 亿美元，复合年增长率为 11.71%。

主要市场统计数据
基准年2024年 361.9亿美元
预计2025年 404.9亿美元
预测年份：2032年 878.1亿美元
复合年增长率（%） 11.71%

血浆蛋白疗法的全面基础介绍，解释其生物学基础、生产复杂性、临床作用和策略系统层级依赖性

血浆蛋白疗法是现代医学的基石，涵盖止血、免疫学和重症加护领域的救生应用。本导论概述了血浆衍生蛋白和重组蛋白的生物学原理，描述了核心生产途径（包括供体采集和分离），并阐述了治疗层级在现代临床实践中的地位。导论重点介绍了这些治疗方法如何应对急性创伤、先天性出血性疾病、免疫力缺乏和标靶预防等疾病，并强调了其供应和交付背后的临床紧迫性和操作复杂性。

引言部分概述了塑造该领域的系统性依赖因素，包括捐赠者的可用性、低温运输物流以及严格的病原体安全通讯协定。此外，引言还重点介绍了重组药物製造和纯化的进展，以及不断发展的患者保护指南，阐明了技术创新与监管之间的相互作用。临床医生要求可预测的供应和一致的临床表现，製造商必须在产能和品管之间取得平衡，而医疗保健系统则需要有弹性的采购途径。这些综合因素为以下章节中对技术变革、贸易动态和细分层面影响的更深入分析提供了背景。

对技术、监管和供应链变革性变化的深刻综合，影响了血浆蛋白疗法的生产、分销和临床应用

一系列融合且具有变革意义的变革正在再形成血浆蛋白疗法的格局，这些变革正在改变血浆蛋白的生产、分销和临床应用。製造技术的进步加速了製程优化，实现了更高的产量、更佳的病毒惰性以及更具可扩展性的分离方法。同时，重组技术和替代表达平台日趋成熟，在传统血浆衍生产品和生物工程替代品之间形成了新的竞争。

疫情期间的混乱和不断升级的地缘政治贸易紧张局势，使供应链的韧性成为重中之重。相关人员目前优先考虑多元化筹资策略、区域能力投资以及数位追溯，以确保持续性。在临床方面，门诊治疗方法提高了患者的便利性，并推动了製剂调整和给药方式的创新。法律规范也在同步发展，更加重视药物安全检测、批次可追溯性和安全标准的跨境协调。总而言之，这些变化需要一项涵盖研发、製造、分销和相关人员参与的整合策略，将科学进步转化为有保障的患者可及性和永续的商业模式。

深入分析美国关税变化如何改变整个血浆治疗生态系统的供应链经济、筹资策略和营运回应

美国近期实施的关税政策变化，为全球血浆疗法供应链的多个环节带来了层层复杂性。对进口原料、专用耗材和某些生技药品征收的关税，不仅增加了到岸成本，改变了供应商的选择标准，也促使製造商重新评估筹资策略和合约条款。这些成本压力将对来自关税上调市场的上游投入产生尤为显着的影响，促使企业考虑近岸外包、战略性库存建设或重新谈判长期供应商合同，以保护利润率并保持供应的连续性。

为应对这项挑战，一些製造商正在加快对国内血浆分离能力的投资，并扩大与区域血浆采集网路的合作，以降低跨境关税波动带来的风险。付款人和采购团队也在重新评估竞标框架和报销途径，以反映调整后的采购成本。同时，监理合规和海关管控日益复杂，需要加强文件编制、提升关税分类专业知识，并进行营运调整以避免延误。最终，这种累积效应将推动全球血浆流动的再平衡，更加重视供应链透明度，并在成本、速度和冗余之间进行务实的权衡，以保障患者用药，同时保持商业性可行性。

深入的、细分主导的观点，详细介绍定义供需动态的产品类别、治疗适应症、给药途径和护理环境

細項分析揭示了产品类别、适应症、给药途径和最终用户的细微趋势，这些趋势影响着临床实践和商业策略。按产品类型，白蛋白对于容量管理和重症加护仍然至关重要，低浓度和高浓度配方适用于各种临床情况。凝血因子，包括具有不同半衰期和给药复杂性的因子，继续导致遗传性和后天性出血性疾病，而凝血酶原复合物浓缩物可快速矫正。针对病原体的高免疫球蛋白製剂为肝炎、狂犬病、破伤风和带状疱疹等疾病提供有针对性的预防和暴露后选择，并在集体爆发应对中保持临床相关性。免疫球蛋白治疗在免疫调节中起着核心作用，可透过静脉或皮下给药，途径的选择会影响患者体验、输液设定和给药频率。

就适应症而言，心血管支持、神经免疫调节、原发性和次发性免疫力缺乏以及创伤相关免疫力缺乏各自驱动不同的需求模式和临床路径。给药途径影响医疗保健提供模式。机构环境中的传统静脉注射与日益普及的皮下给药方式竞争，后者支持家庭给药并降低医院资源利用率。最后，诊所和医院等最终用户表现出不同的采购行为和产能限制。医院通常管理急性住院需求和复杂的仓储物流，而诊所越来越多地支持慢性病管理和分散护理。这些细分为优化可近性和依从性所需的产品开发优先顺序、通路策略和临床支援模型提供了资讯。

区域评估重点关注美洲、中东和非洲以及亚太地区的不同基础设施、监管环境和倡议

在全球血浆蛋白治疗领域，区域动态持续影响产能、可及性和监管导向。美洲地区受益于成熟的捐赠网络、一体化的分馏基础设施以及支持批量收集和配送的物流系统。虽然该地区的产能支撑着可靠的供应，但也面临着成本上涨和监管审查的压力，需要持续投资于品质。

复杂的监管体系和差异化的报销框架决定了欧洲、中东和非洲地区产品供应和应用的节奏。在某些市场，先进的临床路径和强大的医院系统推动着复杂疗法的可及性；而在其他市场，有针对性的可及性项目和能力建设对于扩大利用率至关重要。该地区的政策制定者越来越重视协调可追溯性和安全性，这会影响跨境供应和合规成本。

亚太地区正经历需求快速成长、本地製造投资不断扩大以及血浆采集能力波动的动态组合。医疗保健可近性的提高、临床医生对血浆疗法认知度的提升以及对区域血浆分离能力的策略性投资，正在推动血浆产能扩张。然而，不同市场的供应弹性各不相同，这要求製造商调整分销模式、投资本地伙伴关係关係，并製定教育计划，以使临床实践与一流的安全性和有效性标准保持一致。

清楚概述企业策略，重点在于产能投资、技术差异化、合作伙伴关係和塑造竞争定位的综合服务模式

领先企业和区域性企业之间的竞争动态反映了策略重点，包括产能扩张、产品差异化和垂直整合。老牌製造商持续投资于先进的分馏设施、病原体减少技术，并不断扩展分销网络，以保持供应可靠性和合规性。同时，新兴的生物技术和合约开发公司正在开发重组生产平台和特殊製剂，旨在满足尚未满足的临床需求或提供剂量优势。

策略伙伴关係、授权协议和定向收购已成为现有企业保障产品平臺、取得新技术和扩大地理覆盖范围的常用途径。品质系统、批次一致性和可追溯性是帮助医院和诊所做出采购决策的竞争优势。此外，企业正在扩展患者支援服务，对临床医生进行路线选择和家庭治疗通讯协定的培训，并与付款人合作，使临床表现与报销一致。总而言之，这些发展描绘出一个强调整合解决方案、可预测供应和可证明临床效益作为核心商业要素的市场图景。

领导者提出了一系列切实可行、影响深远的建议，以增强供应弹性、扩大获取管道并加速整个血浆治疗价值链的创新

产业领导者应采取积极主动的议程，解决供应弹性、临床可及性和长期创新问题。首先，透过区域伙伴关係实现采购多元化，并扩大血浆采集网络，可以减轻贸易紧张和关税导致的成本波动的影响。投资模组化、可扩展的生产能力以及先进的病毒灭活和纯化技术，可以提高营运灵活性并增强品质保证。

第二，优先考虑支持门诊和家庭用药的产品和交付创新，特别是透过扩大皮下製剂配方和患者培训倡议。这种转变将减轻医院负担，提高依从性，同时开闢新的销售管道。第三，儘早与监管机构和付款人进行建设性接触，以协调证据产生和报销预期，并简化跨境合规途径。第四，实施强而有力的供应链透明度措施和情境规划，以因应中断，包括策略性库存布局和降低风险的合约条款。最后，透过在整个价值链中部署数位工具并优化捐赠者招募、低温运输监控和药物安全检测，提高可追溯性和营运效率。这些综合行动将在短期韧性与长期竞争力和以患者为中心的成果之间取得平衡。

一种透明的混合方法研究途径，结合主要相关人员访谈、次要技术检验和情境分析，以支持可行的策略见解

本执行摘要所依据的研究采用了混合方法，旨在捕捉营运现状和策略观点。主要的定性研究包括与临床专家、生产主管、采购负责人和监管专业人员进行结构化访谈，以突出该领域的挑战和新兴实践。这些见解与二手文献、行业技术指南和公开的监管文件相结合，以检验趋势并识别技术曲折点。

分析过程采用主题综合法处理质性数据，运用营运图谱评估供应链，并运用情境分析探讨贸易政策变化的影响。研究者仔细考虑了资料来源和来源的三角测量，以减少偏差并增强对定向研究结果的信心。研究的限制包括监管变化的速度不一以及专有製造指标的保密性限制。儘管如此，该调查方法仍强调透明度、可重复性和相关性，以便决策者能够根据临床、营运和监管现状寻求可操作的资讯。

综合技术、供应和政策驱动因素得出明确结论，阐明维持血浆蛋白疗法获取途径和竞争的策略重点

总而言之，虽然血浆蛋白疗法对现代医疗保健仍然至关重要，但该领域正在经历重大变革时期。生产和製剂技术的进步、支持以患者为中心的给药模式的不断发展，以及对供应链韧性的日益重视，正在共同重新定义製造商和医疗保健系统的运作方式。不断变化的贸易政策和不断发展的法规使营运环境进一步复杂化，促使我们采取策略性应对措施，优先考虑本地能力、透明度以及与付款人和监管机构的合作。

展望未来，整合对生产稳健性、创新剂型和有针对性的临床证据生成的投资的组织将最有能力在保持商业性可行性的同时，确保可靠的患者可及性。预测市场波动、调整采购和分销策略以及协调围绕品质和可追溯性的跨职能倡议的能力，将决定谁能在这种复杂的环境中取得成功。因此，相关人员应将这一关键时刻视为一个机会，以现代化营运模式、加强整个价值链的伙伴关係，并在日益以患者为中心的环境中提供可衡量的临床效益。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 重组血浆蛋白製造技术的进步减少了对捐赠者血浆供应的依赖
  • 原发性免疫力缺乏患者越来越多地采用皮下免疫球蛋白治疗
  • 引进新型病毒灭活技术，增强血浆製品安全性
  • 诊断筛检的改进推动了对 α-1 抗胰蛋白酶增强疗法的需求
  • 生物製药公司与血浆采集中心的策略合作扩大了高免疫球蛋白产品组合
  • 下一代凝血因子获得监管部门核准，改善血友病治疗方案
  • 用于单株免疫球蛋白生产的细胞表现平台的出现降低了成本
  • 供应链数位化和低温运输优化确保免疫球蛋白的持续供应

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 血浆蛋白治疗市场（依产品）

  • 白蛋白
    • 5%
    • 25%
  • 凝血因子
    • 凝血因子IX
    • 第八因子
    • 凝血酶原复合物浓缩物
  • 高免疫球蛋白
    • B型肝炎
    • 狂犬病
    • 破伤风
    • 水痘带状疱疹
  • 免疫球蛋白
    • 静脉注射免疫球蛋白
    • 皮下注射免疫球蛋白

9. 血浆蛋白治疗市场（按适应症）

  • 心血管系统
  • 神经系统
  • 原发性免疫力缺乏缺陷症
  • 次发性免疫力缺乏
  • 创伤

10. 依给药途径分類的血浆蛋白治疗市场

  • 肌肉注射
  • 静脉
  • 口服
  • 皮下

第 11 章。血浆蛋白治疗市场（按最终用户）

  • 诊所
  • 医院

12. 血浆蛋白治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章血浆蛋白治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 血浆蛋白治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • CSL Behring LLC
    • Takeda Pharmaceutical Company Limited
    • Grifols, SA
    • Octapharma AG
    • Biotest AG
    • Baxter International Inc.
    • Kedrion SpA
    • LFB SA
    • Pfizer Inc.
    • ADMA Biologics
Product Code: MRR-030EE4851670

The Plasma Protein Therapeutics Market is projected to grow by USD 87.81 billion at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.19 billion
Estimated Year [2025] USD 40.49 billion
Forecast Year [2032] USD 87.81 billion
CAGR (%) 11.71%

A comprehensive foundational introduction that explains the biological basis, production complexity, clinical roles, and strategic system-level dependencies of plasma protein therapeutics

Plasma protein therapeutics constitute a cornerstone of modern clinical care, spanning life-saving applications in hemostasis, immunology, and critical care. This introduction frames the biological rationale for plasma-derived and recombinant proteins, explains core production pathways such as donor collection and fractionation, and situates therapeutic classes within contemporary clinical practice. It highlights how these therapies address acute trauma, congenital bleeding disorders, immune deficiencies, and targeted prophylaxis, emphasizing both the clinical urgency and the operational complexity that underpin supply and delivery.

Moreover, the introduction outlines systemic dependencies that shape the sector, including donor availability, cold-chain logistics, and rigorous pathogen safety protocols. It presents the interplay between innovation and regulation, noting advances in recombinant production and purification alongside evolving guidance to safeguard patients. Finally, it clarifies the strategic stakes for stakeholders: clinicians require predictable supply and consistent clinical performance, manufacturers must balance capacity and quality controls, and health systems need resilient procurement pathways. Together, these elements create the context for deeper analysis of technological shifts, trade dynamics, and segmentation-level implications provided in the subsequent sections.

An insightful synthesis of transformative technological, regulatory, and supply chain shifts reshaping production, distribution, and clinical adoption of plasma protein therapies

The landscape for plasma protein therapeutics has been reshaped by a set of convergent, transformative shifts that alter production, distribution, and clinical use. Advances in manufacturing technologies have accelerated process optimization, enabling higher yields, improved viral inactivation, and more scalable fractionation approaches. At the same time, recombinant techniques and alternative expression platforms are maturing, creating new competitive dynamics between traditional plasma-derived products and biologically engineered alternatives.

Supply chain resilience has moved to the forefront, driven by pandemic-era disruptions and heightened geopolitical trade friction. Stakeholders now prioritize diversified sourcing strategies, regional capacity investments, and digital traceability to ensure continuity. Clinically, there is a clear pivot toward therapies that enable outpatient administration and improved patient convenience, prompting formulation adaptations and delivery innovations. Regulatory frameworks are evolving in parallel, with greater emphasis on pharmacovigilance, batch traceability, and cross-border harmonization of safety standards. Taken together, these shifts demand integrated strategies across R&D, manufacturing, distribution, and stakeholder engagement to translate scientific advances into reliable patient access and sustainable commercial models.

A detailed analysis of how evolving United States tariff measures are altering supply chain economics, sourcing strategies, and operational responses across the plasma therapeutics ecosystem

Recent tariff policy changes implemented by the United States have introduced a layer of complexity that affects multiple nodes of the global plasma therapeutics supply chain. Tariffs on imported raw materials, specialized consumables, and certain finished biologics increase landed costs and alter supplier selection criteria, prompting manufacturers to re-evaluate sourcing strategies and contractual terms. These cost pressures are disproportionately felt where upstream inputs originate from markets subject to elevated duties, leading firms to consider nearshoring, strategic inventory buildup, or renegotiation of long-term supplier agreements to protect margins and maintain supply continuity.

In response, some manufacturers are accelerating investments in domestic fractionation capacity and expanding partnerships with regional plasma collection networks to reduce exposure to cross-border tariff volatility. Payers and procurement teams are also reassessing tender frameworks and reimbursement pathways to reflect adjusted acquisition costs. Meanwhile, regulatory compliance and customs administration become more complex, requiring enhanced documentation, tariff classification expertise, and operational adjustments to avoid delays. Ultimately, the cumulative effect incentivizes a rebalancing of global flows, greater emphasis on supply chain transparency, and pragmatic trade-offs between cost, speed, and redundancy to protect patient access while preserving commercial viability.

A thorough segmentation-driven perspective detailing product classes, therapeutic indications, administration routes, and care settings that define demand and delivery dynamics

Segmentation analysis reveals nuanced trends across product classes, indications, routes of administration, and end users that shape clinical practice and commercial strategy. Within product categories, albumin remains critical for volume management and critical care, with formulations spanning lower and higher concentration presentations suited to different clinical scenarios. Coagulation factors continue to serve hereditary and acquired bleeding disorders, including products for factors that vary in half-life and administration complexity, while prothrombin complex concentrates offer rapid correction capabilities. Hyperimmune globulins tailored to specific pathogens provide targeted prophylaxis and post-exposure options for diseases such as hepatitis, rabies, tetanus, and varicella zoster, and they retain clinical relevance in outbreak responses. Immunoglobulin therapies maintain a central role in immune modulation, delivered either intravenously or via subcutaneous routes, with route choice influencing patient experience, infusion setting, and dosing cadence.

Regarding indications, cardiovascular support, neurological immune modulation, primary and secondary immunodeficiencies, and trauma-related resuscitation each drive distinct demand patterns and clinical pathways. Routes of administration influence healthcare delivery models: traditional intravenous delivery in institutional settings competes with growing adoption of subcutaneous alternatives that enable home administration and reduce hospital resource utilization. Finally, end users such as clinics and hospitals demonstrate different procurement behaviors and capacity constraints; hospitals typically manage acute inpatient demand and complex storage logistics, whereas clinics increasingly support chronic therapy administration and decentralized care. Together, these segmentation layers inform product development priorities, channel strategies, and clinical support models needed to optimize access and adherence.

A nuanced regional assessment highlighting the differing infrastructure, regulatory landscapes, and capacity initiatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to influence capacity, access, and regulatory navigation across the global continuum of plasma protein therapeutics. The Americas landscape benefits from a well-established donor network, integrated fractionation infrastructure, and logistical systems that support high-volume collection and distribution. This regional capability underpins supply reliability but also faces pressure from cost inflation and regulatory scrutiny that demand continuous quality investments.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement frameworks shape product availability and adoption rhythms. Some markets feature advanced clinical pathways and robust hospital systems that drive complex therapy utilization, while others require targeted access programs and capacity building to expand availability. Policymakers in the region are increasingly focused on traceability and safety harmonization, which affects cross-border supply and compliance costs.

Asia-Pacific presents a dynamic mix of rapid demand growth, expanding local manufacturing investments, and variable plasma collection capacity. Increasing healthcare access, rising clinician awareness of plasma therapies, and strategic investments in regional fractionation capabilities are fostering capacity expansion. However, supply resilience remains uneven across markets, requiring manufacturers to tailor distribution models, invest in local partnerships, and deploy education programs to align clinical practice with best-in-class safety and efficacy standards.

An incisive overview of company strategies emphasizing capacity investment, technological differentiation, alliances, and integrated service models that shape competitive positioning

Competitive dynamics among leading firms and regional players reflect strategic priorities that include capacity expansion, product differentiation, and vertical integration. Established manufacturers continue to invest in state-of-the-art fractionation facilities, pathogen reduction technologies, and extended distribution networks to maintain supply reliability and regulatory compliance. At the same time, emerging biotechnology companies and contract developers are advancing recombinant production platforms and specialty formulations intended to address unmet clinical needs or offer administration advantages.

Strategic partnerships, licensing agreements, and targeted acquisitions have become common pathways for incumbents to secure product pipelines, access novel technologies, or strengthen regional footprints. Quality systems, lot-to-lot consistency, and traceability are competitive differentiators that inform procurement decisions by hospitals and clinics. Additionally, companies are expanding patient support services, educating clinicians on route selection and home-based therapy protocols, and collaborating with payers to align reimbursement with clinical outcomes. These combined moves illustrate a marketplace that values integrated solutions, predictable supply, and demonstrable clinical benefit as core commercial imperatives.

A set of pragmatic, high-impact recommendations for leaders to strengthen supply resilience, broaden access, and accelerate innovation across the plasma therapeutics value chain

Industry leaders should adopt a proactive agenda that addresses supply resilience, clinical accessibility, and long-term innovation. First, diversifying sourcing through regional partnerships and expanding plasma collection networks can reduce exposure to trade friction and tariff-driven cost volatility. Investing in modular and scalable manufacturing capacity, as well as advanced viral inactivation and purification technologies, will improve operational flexibility and strengthen quality assurance.

Second, prioritize product and delivery innovations that support outpatient and home-based administration, particularly by expanding subcutaneous formulations and patient training initiatives. These shifts reduce hospital burden and enhance adherence while opening new commercial channels. Third, engage early and constructively with regulators and payers to align evidence generation with reimbursement expectations and to streamline cross-border compliance pathways. Fourth, implement robust supply chain transparency measures and scenario planning to manage disruptions, including strategic inventory positioning and contractual clauses that mitigate risk. Finally, embed digital tools across the value chain to optimize donor recruitment, cold-chain monitoring, and pharmacovigilance, thereby enhancing traceability and operational efficiency. Together, these actions will balance short-term resilience with long-term competitiveness and patient-centered outcomes.

A transparent mixed-methods research approach combining primary stakeholder interviews, secondary technical validation, and scenario analysis to support actionable strategic insights

The research underpinning this executive summary employed a mixed-methods approach designed to capture both operational realities and strategic perspectives. Primary qualitative engagement included structured interviews with clinical specialists, manufacturing leaders, procurement officers, and regulatory experts to surface frontline challenges and emergent practices. These insights were triangulated with secondary literature, industry technical guidance, and publicly available regulatory documents to validate trends and identify technological inflection points.

Analytical processes applied thematic synthesis for qualitative data, operational mapping for supply chain assessment, and scenario analysis to explore the implications of trade policy shifts. Careful attention was given to data provenance and source triangulation to limit bias and increase confidence in directional findings. Limitations include the variable speed of regulatory changes and the confidentiality constraints around proprietary manufacturing metrics, both of which can limit granularity. Nevertheless, the methodology emphasizes transparency, reproducibility, and relevance for decision-makers seeking actionable intelligence grounded in clinical, operational, and regulatory realities.

A decisive conclusion synthesizing technological, supply, and policy drivers to clarify strategic priorities for sustaining access and competitiveness in plasma protein therapies

In conclusion, plasma protein therapeutics remain indispensable to modern healthcare, yet the sector is navigating a period of significant transformation. Technological advances in production and formulation, evolving administration paradigms that favor patient-centric delivery, and heightened attention to supply chain resilience collectively redefine how manufacturers and health systems must operate. Trade policy shifts and regulatory evolution further complicate the operating environment, prompting strategic responses that prioritize regional capacity, transparency, and collaborative engagement with payers and regulators.

Moving forward, organizations that integrate investments in manufacturing robustness, innovative delivery formats, and targeted clinical evidence generation will be best positioned to sustain reliable patient access while preserving commercial viability. The ability to anticipate disruptions, adapt procurement and distribution strategies, and align cross-functional initiatives around quality and traceability will determine who succeeds in this complex landscape. Stakeholders should therefore view this juncture as an opportunity to modernize operational models, strengthen partnerships across the value chain, and deliver measurable clinical benefit in an increasingly patient-centric environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in recombinant plasma protein manufacturing reducing reliance on donor plasma supply
  • 5.2. Increasing adoption of subcutaneous immunoglobulin therapies for primary immunodeficiency patients
  • 5.3. Implementation of novel viral inactivation techniques enhancing safety of fractionated plasma products
  • 5.4. Rising demand for alpha-1 antitrypsin augmentation therapy driven by better diagnostic screening
  • 5.5. Strategic collaborations between biopharma and plasma collection centers to expand hyperimmune globulin portfolios
  • 5.6. Regulatory approvals for next-generation coagulation factors improving treatment options for hemophilia
  • 5.7. Emergence of cell-based expression platforms for monoclonal immunoglobulin production reducing costs
  • 5.8. Supply chain digitalization and cold chain optimization ensuring uninterrupted immunoglobulin availability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Protein Therapeutics Market, by Product

  • 8.1. Albumin
    • 8.1.1. Five Percent
    • 8.1.2. Twenty Five Percent
  • 8.2. Coagulation Factor
    • 8.2.1. Factor IX
    • 8.2.2. Factor VIII
    • 8.2.3. Prothrombin Complex Concentrate
  • 8.3. Hyperimmune Globulin
    • 8.3.1. Hepatitis B
    • 8.3.2. Rabies
    • 8.3.3. Tetanus
    • 8.3.4. Varicella Zoster
  • 8.4. Immunoglobulin
    • 8.4.1. Intravenous Immunoglobulin
    • 8.4.2. Subcutaneous Immunoglobulin

9. Plasma Protein Therapeutics Market, by Indication

  • 9.1. Cardiovascular
  • 9.2. Neurological
  • 9.3. Primary Immunodeficiency
  • 9.4. Secondary Immunodeficiency
  • 9.5. Trauma

10. Plasma Protein Therapeutics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Plasma Protein Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals

12. Plasma Protein Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Plasma Protein Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Plasma Protein Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. CSL Behring LLC
    • 15.3.2. Takeda Pharmaceutical Company Limited
    • 15.3.3. Grifols, S.A.
    • 15.3.4. Octapharma AG
    • 15.3.5. Biotest AG
    • 15.3.6. Baxter International Inc.
    • 15.3.7. Kedrion S.p.A.
    • 15.3.8. LFB S.A.
    • 15.3.9. Pfizer Inc.
    • 15.3.10. ADMA Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA PLASMA PROTEIN THERAPEUT